Atlas Trials

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Clinical trial NCT04985136 · TERMINATED

Trial details

NCT number
NCT04985136
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Hepatocellular Carcinoma (HCC)
Start date
2021-09-26
Primary completion
2021-12-29
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.